insulin NPH vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin NPH · Humulin N

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin NPHTHDB0206
HbA1c, change—Not posted · NCT00604396—Not posted · NCT05834868
Body weight, change (kg)12.6 vs 13vs Levemirn 42NCT01837680—Not posted · NCT05834868
HbA1c below 7%—Not posted · NCT00604396—Not posted · NCT05834868
Fasting plasma glucose, change—Not posted · NCT00604396—Not posted · NCT05834868
3-point MACE (% with event)—Not posted · NCT00604396—Not posted · NCT05834868

HbA1c, change

insulin NPH
—Not posted · NCT00604396
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

insulin NPH
12.6 vs 13vs Levemirn 42NCT01837680
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

insulin NPH
—Not posted · NCT00604396
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

insulin NPH
—Not posted · NCT00604396
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

insulin NPH
—Not posted · NCT00604396
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin NPH: 3 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin NPH
Dropout rate
19.2%a
NCT01837680 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01837680 · Phase na · registry result, not featured evidence
Serious AEs
0%a
NCT01837680 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
biochemical event of hypoglycemia 26.9%
symptomatic hypoglycemia 21.2%
rash 11.5%
NCT01837680 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin NPH

Glucose mg/dL 6.08 vs 5.96 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 109.5 mg/dL as posted
Glucose Target Attainment 66.7% (n=42) vs 77.8% (n=45) Levemir
event count · % of participants
NCT01837680 · Phase na · registry result, not featured evidence · converted to % from 28 Participants as posted
Time to Glycemic Control 1.15 vs 1.15 Levemir months
time to event · months
NCT01837680 · Phase na · registry result, not featured evidence · converted to months from 5 weeks as posted
Fasting Plasma Glucose mg/dL 5.59 vs 5.4 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 100.7 mg/dL as posted
Postprandial Plasma Glucose mg/dL 6.39 vs 6.27 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 115.2 mg/dL as posted
Weight 12.6 vs 13 Levemir kg
absolute change · kg
NCT01837680 · Phase na · registry result, not featured evidence · converted to kg from 27.7 lbs as posted
Birth Weight Grams 3230 vs 3235 Levemir g
absolute value · g
NCT01837680 · Phase na · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin NPH's landscape · THDB0206's landscape